# OnCo record izalontamab-brengitecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/izalontamab-brengitecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "izalontamab-brengitecan" ;
  schema:name "Izalontamab brengitecan"@en ;
  schema:description "Izalontamab brengitecan is the first bispecific ADC to succeed in a phase 3 trial, hitting two growth receptors at once in triple-negative breast cancer."@en ;
  schema:url <https://onco.cc/drugs/izalontamab-brengitecan/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.onclive.com/view/iza-bren-yields-pfs-and-os-benefits-vs-chemo-in-previously-treated-advanced-tnbc> ;
  onco:status "phase-3" ;
  onco:modality "Bispecific ADC" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her3/> ;
  onco:companies <https://onco.cc/companies/systimmune/>, <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/hydrophilic-next-gen/> ;
  onco:trials <https://onco.cc/trials/bl-b01d1-307/>, <https://onco.cc/trials/izabright-breast01/>, <https://onco.cc/trials/nct06838273/>, <https://onco.cc/trials/nct07502300/>, <https://onco.cc/trials/nct06382129/>, <https://onco.cc/trials/nct07640789/>, <https://onco.cc/trials/nct06994195/>, <https://onco.cc/trials/nct06118333/>, <https://onco.cc/trials/nct07642024/>, <https://onco.cc/trials/nct07100080/>, <https://onco.cc/trials/nct06500026/>, <https://onco.cc/trials/nct06382116/>, <https://onco.cc/trials/nct06475300/>, <https://onco.cc/trials/nct06498986/>, <https://onco.cc/trials/nct06437522/>, <https://onco.cc/trials/nct07054567/>, <https://onco.cc/trials/nct05880706/>, <https://onco.cc/trials/nct05956587/>, <https://onco.cc/trials/nct05990803/>, <https://onco.cc/trials/nct06006169/>, <https://onco.cc/trials/nct05924841/>, <https://onco.cc/trials/nct06008054/>, <https://onco.cc/trials/nct06437509/>, <https://onco.cc/trials/nct06787664/> .